KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Deferred Taxes (2017 - 2023)

BeOne Medicines (ONC) has disclosed Deferred Taxes for 7 consecutive years, with -$46000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Deferred Taxes fell 102.74% to -$46000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was -$5.5 million, a 367.17% decrease, with the full-year FY2025 number at $9.5 million, down 63.56% from a year prior.
  • Deferred Taxes was -$46000.0 for Q4 2023 at BeOne Medicines, down from $36000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $14.8 million in Q3 2021 to a low of -$19.0 million in Q4 2020.
  • A 5-year average of -$1.8 million and a median of -$339500.0 in 2019 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: plummeted 5847.09% in 2021, then skyrocketed 21493.33% in 2022.
  • BeOne Medicines' Deferred Taxes stood at $4.1 million in 2019, then crashed by 564.29% to -$19.0 million in 2020, then skyrocketed by 104.74% to $903000.0 in 2021, then soared by 85.94% to $1.7 million in 2022, then crashed by 102.74% to -$46000.0 in 2023.
  • Per Business Quant, the three most recent readings for ONC's Deferred Taxes are -$46000.0 (Q4 2023), $36000.0 (Q1 2023), and $1.7 million (Q4 2022).